HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

doi:10.1016/S0140-6736(14)61183-1

Meta-Analysis

. 2015 Jan 24;385(9965):351-61.

doi: 10.1016/S0140-6736(14)61183-1. Epub 2014 Sep 24.

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Daniel I Swerdlow¹, David Preiss², Karoline B Kuchenbaecker³, Michael V Holmes⁴, Jorgen E L Engmann⁴, Tina Shah⁴, Reecha Sofat⁵, Stefan Stender⁶, Paul C D Johnson⁷, Robert A Scott⁸, Maarten Leusink⁹, Niek Verweij¹⁰, Stephen J Sharp⁸, Yiran Guo¹¹, Claudia Giambartolomei¹², Christina Chung¹³, Anne Peasey¹³, Antoinette Amuzu¹⁴, KaWah Li¹⁵, Jutta Palmen¹⁵, Philip Howard¹⁵, Jackie A Cooper¹⁵, Fotios Drenos¹⁵, Yun R Li¹¹, Gordon Lowe¹⁶, John Gallacher¹⁷, Marlene C W Stewart¹⁸, Ioanna Tzoulaki¹⁹, Sarah G Buxbaum²⁰, Daphne L van der A²¹, Nita G Forouhi⁸, N Charlotte Onland-Moret²², Yvonne T van der Schouw²², Renate B Schnabel²³, Jaroslav A Hubacek²⁴, Ruzena Kubinova²⁵, Migle Baceviciene²⁶, Abdonas Tamosiunas²⁷, Andrzej Pajak²⁸, Roman Topor-Madry²⁸, Urszula Stepaniak²⁸, Sofia Malyutina²⁹, Damiano Baldassarre³⁰, Bengt Sennblad³¹, Elena Tremoli³⁰, Ulf de Faire³², Fabrizio Veglia³³, Ian Ford⁷, J Wouter Jukema³⁴, Rudi G J Westendorp³⁵, Gert Jan de Borst³⁶, Pim A de Jong³⁷, Ale Algra³⁸, Wilko Spiering³⁹, Anke H Maitland-van der Zee⁹, Olaf H Klungel⁹, Anthonius de Boer⁹, Pieter A Doevendans⁴⁰, Charles B Eaton⁴¹, Jennifer G Robinson⁴², David Duggan⁴³; DIAGRAM Consortium; MAGIC Consortium; InterAct Consortium; John Kjekshus⁴⁴, John R Downs⁴⁵, Antonio M Gotto⁴⁶, Anthony C Keech⁴⁷, Roberto Marchioli⁴⁸, Gianni Tognoni⁴⁹, Peter S Sever⁵⁰, Neil R Poulter⁵⁰, David D Waters⁵¹, Terje R Pedersen⁵², Pierre Amarenco⁵³, Haruo Nakamura⁵⁴, John J V McMurray⁵⁵, James D Lewsey⁵⁶, Daniel I Chasman⁵⁷, Paul M Ridker⁵⁷, Aldo P Maggioni⁵⁸, Luigi Tavazzi⁵⁹, Kausik K Ray⁶⁰, Sreenivasa Rao Kondapally Seshasai⁶⁰, JoAnn E Manson⁵⁷, Jackie F Price¹⁸, Peter H Whincup⁶¹, Richard W Morris⁶², Debbie A Lawlor⁶³, George Davey Smith⁶³, Yoav Ben-Shlomo⁶⁴, Pamela J Schreiner⁶⁵, Myriam Fornage⁶⁶, David S Siscovick⁶⁷, Mary Cushman⁶⁸, Meena Kumari¹³, Nick J Wareham⁸, W M Monique Verschuren²¹, Susan Redline⁶⁹, Sanjay R Patel⁷⁰, John C Whittaker⁷¹, Anders Hamsten⁷², Joseph A Delaney⁷³, Caroline Dale⁷⁴, Tom R Gaunt⁷⁵, Andrew Wong⁷⁶, Diana Kuh⁷⁶, Rebecca Hardy⁷⁶, Sekar Kathiresan⁷⁷, Berta A Castillo¹¹, Pim van der Harst¹⁰, Eric J Brunner¹³, Anne Tybjaerg-Hansen⁶, Michael G Marmot¹³, Ronald M Krauss⁷⁸, Michael Tsai⁷⁹, Josef Coresh⁸⁰, Ronald C Hoogeveen⁸¹, Bruce M Psaty⁶⁷, Leslie A Lange⁸², Hakon Hakonarson¹¹, Frank Dudbridge¹⁴, Steve E Humphries¹⁵, Philippa J Talmud¹⁵, Mika Kivimäki¹³, Nicholas J Timpson⁶³, Claudia Langenberg⁸, Folkert W Asselbergs⁸³, Mikhail Voevoda⁸⁴, Martin Bobak¹³, Hynek Pikhart¹³, James G Wilson⁸⁵, Alex P Reiner⁸⁶, Brendan J Keating¹¹, Aroon D Hingorani⁴, Naveed Sattar⁵⁵

Affiliations

¹ UCL Institute of Cardiovascular Science and Farr Institute, University College London, London, UK. Electronic address: d.swerdlow@ucl.ac.uk.
² BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Electronic address: david.preiss@glasgow.ac.uk.
³ Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; Department of Surgery, Division of Transplantation, and Clinical Epidemiology Unit, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁴ UCL Institute of Cardiovascular Science and Farr Institute, University College London, London, UK.
⁵ UCL Department of Medicine, University College London, London, UK.
⁶ Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
⁷ Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
⁸ MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, UK.
⁹ Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands.
¹⁰ University of Groningen, University Medical Centre Groningen, Department of Cardiology, Groningen, Netherlands.
¹¹ Center for Applied Genomics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
¹² UCL Genetics Institute, University College London, London, UK.
¹³ UCL Research Department of Epidemiology and Public Health, University College London, London, UK.
¹⁴ London School of Hygiene & Tropical Medicine, London, UK.
¹⁵ Centre for Cardiovascular Genetics, University College London, London, UK.
¹⁶ Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
¹⁷ Department of Primary Care and Public Health, Cardiff University Medical School, Cardiff University, Cardiff, UK.
¹⁸ Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK.
¹⁹ Department of Epidemiology and Biostatistics, Imperial College London, London, UK.
²⁰ Jackson State University, Jackson, MS, USA.
²¹ National Institute for Public Health and the Environment, Bilthoven, Netherlands.
²² Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands.
²³ University Heart Center Hamburg, Department of General and Interventional Cardiology, Hamburg, Germany.
²⁴ Centre for Experimental Medicine, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
²⁵ National Institute of Public Health, Prague, Czech Republic.
²⁶ Lithuanian University of Health Sciences, Kaunas, Lithuania.
²⁷ Institute of Cardiology, Kaunas, Lithuania.
²⁸ Department of Epidemiology and Population Studies, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland.
²⁹ Institute of Internal and Preventive Medicine, Siberian Branch of Russian Academy of Medical Sciences, Novosibirsk, Russia.
³⁰ Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Milan, Italy; Centro Cardiologico Monzino IRCCS Milan, Milan, Italy.
³¹ Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.
³² Division of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
³³ Biostatistics Unit, Milan, Italy.
³⁴ Department of Cardiology, Leiden University Medical Center, Leiden, Netherlands.
³⁵ Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, Netherlands.
³⁶ Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, Netherlands.
³⁷ Department of Radiology, University Medical Center Utrecht, Utrecht, Netherlands.
³⁸ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands; Department of Neurology and Neurosurgery, University Medical Center Utrecht, Utrecht, Netherlands.
³⁹ Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, Netherlands.
⁴⁰ Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, Netherlands.
⁴¹ Memorial Hospital of Rhode Island, RI, USA.
⁴² University of Iowa, IA, USA.
⁴³ Translational Genomics Research Institute, Phoenix, AZ, USA.
⁴⁴ Department of Cardiology, Oslo University Hospital Rikshospitalet, University of Oslo, Oslo, Norway.
⁴⁵ Department of Medicine, University of Texas Health Science Centre, San Antonio, TX, USA; VERDICT, South Texas Veterans Health Care System, San Antonio, TX, USA.
⁴⁶ Weill Cornell Medical College, New York, NY, USA.
⁴⁷ NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
⁴⁸ Hematology and Oncology Therapeutic Delivery Unit, Quintiles, Milan, Italy.
⁴⁹ Department of Clinical Pharmacology and Epidemiology, Consorzio Mario NegriSud, Santa Maria Imbaro, Chieti, Italy.
⁵⁰ International Centre for Circulatory Health, Imperial College London, London, UK.
⁵¹ Department of Medicine, University of California, San Francisco, CA, USA.
⁵² Centre for Preventative Medicine, Oslo University Hospital Rikshospitalet, University of Oslo, Oslo, Norway.
⁵³ Denis Diderot University, Paris, France.
⁵⁴ Mitsukoshi Health and Welfare Foundation, Tokyo, Japan.
⁵⁵ BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
⁵⁶ Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
⁵⁷ Division of Preventive Medicine, Boston, MA, USA.
⁵⁸ ANMCO Research Center, Florence, Italy.
⁵⁹ Maria Cecilia Hospital, GVM Care and Research, E.S. Health Science Foundation, Cotignola (RA), Italy.
⁶⁰ Cardiac and Cell Sciences Research Institute, London, UK.
⁶¹ St George's University of London, London, UK.
⁶² UCL Department of Primary Care and Population Health, University College London, London, UK.
⁶³ MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK; School of Social and Community Medicine, University of Bristol, Bristol, UK.
⁶⁴ School of Social and Community Medicine, University of Bristol, Bristol, UK.
⁶⁵ School of Public Health, Minneapolis, MN, USA.
⁶⁶ Institute of Molecular Medicine and Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA.
⁶⁷ Cardiovascular Health Research Unit of the Department of Medicine, Department of Epidemiology, and Department of Health Services, University of Washington, Seattle, WA, USA.
⁶⁸ Departments of Medicine and Pathology, University of Vermont, Colchester, VT, USA.
⁶⁹ Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁷⁰ Division of Sleep Medicine, Boston, MA, USA.
⁷¹ GlaxoSmithKline, Stevenage, UK.
⁷² Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
⁷³ Department of Epidemiology, University of Washington, Seattle, WA, USA.
⁷⁴ Department of Non-Communicable Disease Epidemiology, London, UK.
⁷⁵ MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
⁷⁶ MRCUnit for Lifelong Health and Ageing, Institute of Epidemiology and Health Care, University College London, London, UK.
⁷⁷ Cardiology Division, Massachusetts General Hospital, Boston, MA, USA; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA.
⁷⁸ Children's Hospital Oakland Research Institute, Oakland, CA USA.
⁷⁹ University of Minnesota, Minneapolis, MN, USA.
⁸⁰ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
⁸¹ Baylor College of Medicine, Department of Medicine, Division of Atherosclerosis and Vascular Medicine, Houston, TX, USA.
⁸² Department of Genetics, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA.
⁸³ UCL Institute of Cardiovascular Science and Farr Institute, University College London, London, UK; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, Netherlands; Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, Netherlands.
⁸⁴ Institute of Internal and Preventive Medicine, Siberian Branch of Russian Academy of Medical Sciences, Novosibirsk, Russia; Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Medical Sciences, Novosibirsk, Russia.
⁸⁵ Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA.
⁸⁶ Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

PMID: 25262344
PMCID: PMC4322187
DOI: 10.1016/S0140-6736(14)61183-1

Meta-Analysis

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Daniel I Swerdlow et al. Lancet. 2015.

. 2015 Jan 24;385(9965):351-61.

doi: 10.1016/S0140-6736(14)61183-1. Epub 2014 Sep 24.

Authors

Affiliations

¹ UCL Institute of Cardiovascular Science and Farr Institute, University College London, London, UK. Electronic address: d.swerdlow@ucl.ac.uk.
² BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Electronic address: david.preiss@glasgow.ac.uk.
³ Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; Department of Surgery, Division of Transplantation, and Clinical Epidemiology Unit, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁴ UCL Institute of Cardiovascular Science and Farr Institute, University College London, London, UK.
⁵ UCL Department of Medicine, University College London, London, UK.
⁶ Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
⁷ Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
⁸ MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, UK.
⁹ Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands.
¹⁰ University of Groningen, University Medical Centre Groningen, Department of Cardiology, Groningen, Netherlands.
¹¹ Center for Applied Genomics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
¹² UCL Genetics Institute, University College London, London, UK.
¹³ UCL Research Department of Epidemiology and Public Health, University College London, London, UK.
¹⁴ London School of Hygiene & Tropical Medicine, London, UK.
¹⁵ Centre for Cardiovascular Genetics, University College London, London, UK.
¹⁶ Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
¹⁷ Department of Primary Care and Public Health, Cardiff University Medical School, Cardiff University, Cardiff, UK.
¹⁸ Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK.
¹⁹ Department of Epidemiology and Biostatistics, Imperial College London, London, UK.
²⁰ Jackson State University, Jackson, MS, USA.
²¹ National Institute for Public Health and the Environment, Bilthoven, Netherlands.
²² Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands.
²³ University Heart Center Hamburg, Department of General and Interventional Cardiology, Hamburg, Germany.
²⁴ Centre for Experimental Medicine, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
²⁵ National Institute of Public Health, Prague, Czech Republic.
²⁶ Lithuanian University of Health Sciences, Kaunas, Lithuania.
²⁷ Institute of Cardiology, Kaunas, Lithuania.
²⁸ Department of Epidemiology and Population Studies, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland.
²⁹ Institute of Internal and Preventive Medicine, Siberian Branch of Russian Academy of Medical Sciences, Novosibirsk, Russia.
³⁰ Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Milan, Italy; Centro Cardiologico Monzino IRCCS Milan, Milan, Italy.
³¹ Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.
³² Division of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
³³ Biostatistics Unit, Milan, Italy.
³⁴ Department of Cardiology, Leiden University Medical Center, Leiden, Netherlands.
³⁵ Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, Netherlands.
³⁶ Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, Netherlands.
³⁷ Department of Radiology, University Medical Center Utrecht, Utrecht, Netherlands.
³⁸ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands; Department of Neurology and Neurosurgery, University Medical Center Utrecht, Utrecht, Netherlands.
³⁹ Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, Netherlands.
⁴⁰ Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, Netherlands.
⁴¹ Memorial Hospital of Rhode Island, RI, USA.
⁴² University of Iowa, IA, USA.
⁴³ Translational Genomics Research Institute, Phoenix, AZ, USA.
⁴⁴ Department of Cardiology, Oslo University Hospital Rikshospitalet, University of Oslo, Oslo, Norway.
⁴⁵ Department of Medicine, University of Texas Health Science Centre, San Antonio, TX, USA; VERDICT, South Texas Veterans Health Care System, San Antonio, TX, USA.
⁴⁶ Weill Cornell Medical College, New York, NY, USA.
⁴⁷ NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
⁴⁸ Hematology and Oncology Therapeutic Delivery Unit, Quintiles, Milan, Italy.
⁴⁹ Department of Clinical Pharmacology and Epidemiology, Consorzio Mario NegriSud, Santa Maria Imbaro, Chieti, Italy.
⁵⁰ International Centre for Circulatory Health, Imperial College London, London, UK.
⁵¹ Department of Medicine, University of California, San Francisco, CA, USA.
⁵² Centre for Preventative Medicine, Oslo University Hospital Rikshospitalet, University of Oslo, Oslo, Norway.
⁵³ Denis Diderot University, Paris, France.
⁵⁴ Mitsukoshi Health and Welfare Foundation, Tokyo, Japan.
⁵⁵ BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
⁵⁶ Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
⁵⁷ Division of Preventive Medicine, Boston, MA, USA.
⁵⁸ ANMCO Research Center, Florence, Italy.
⁵⁹ Maria Cecilia Hospital, GVM Care and Research, E.S. Health Science Foundation, Cotignola (RA), Italy.
⁶⁰ Cardiac and Cell Sciences Research Institute, London, UK.
⁶¹ St George's University of London, London, UK.
⁶² UCL Department of Primary Care and Population Health, University College London, London, UK.
⁶³ MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK; School of Social and Community Medicine, University of Bristol, Bristol, UK.
⁶⁴ School of Social and Community Medicine, University of Bristol, Bristol, UK.
⁶⁵ School of Public Health, Minneapolis, MN, USA.
⁶⁶ Institute of Molecular Medicine and Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA.
⁶⁷ Cardiovascular Health Research Unit of the Department of Medicine, Department of Epidemiology, and Department of Health Services, University of Washington, Seattle, WA, USA.
⁶⁸ Departments of Medicine and Pathology, University of Vermont, Colchester, VT, USA.
⁶⁹ Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁷⁰ Division of Sleep Medicine, Boston, MA, USA.
⁷¹ GlaxoSmithKline, Stevenage, UK.
⁷² Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
⁷³ Department of Epidemiology, University of Washington, Seattle, WA, USA.
⁷⁴ Department of Non-Communicable Disease Epidemiology, London, UK.
⁷⁵ MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
⁷⁶ MRCUnit for Lifelong Health and Ageing, Institute of Epidemiology and Health Care, University College London, London, UK.
⁷⁷ Cardiology Division, Massachusetts General Hospital, Boston, MA, USA; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA.
⁷⁸ Children's Hospital Oakland Research Institute, Oakland, CA USA.
⁷⁹ University of Minnesota, Minneapolis, MN, USA.
⁸⁰ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
⁸¹ Baylor College of Medicine, Department of Medicine, Division of Atherosclerosis and Vascular Medicine, Houston, TX, USA.
⁸² Department of Genetics, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA.
⁸³ UCL Institute of Cardiovascular Science and Farr Institute, University College London, London, UK; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, Netherlands; Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, Netherlands.
⁸⁴ Institute of Internal and Preventive Medicine, Siberian Branch of Russian Academy of Medical Sciences, Novosibirsk, Russia; Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Medical Sciences, Novosibirsk, Russia.
⁸⁵ Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA.
⁸⁶ Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

PMID: 25262344
PMCID: PMC4322187
DOI: 10.1016/S0140-6736(14)61183-1

Abstract

Background: Statins increase the risk of new-onset type 2 diabetes mellitus. We aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug target.

Methods: We used single nucleotide polymorphisms in the HMGCR gene, rs17238484 (for the main analysis) and rs12916 (for a subsidiary analysis) as proxies for HMGCR inhibition by statins. We examined associations of these variants with plasma lipid, glucose, and insulin concentrations; bodyweight; waist circumference; and prevalent and incident type 2 diabetes. Study-specific effect estimates per copy of each LDL-lowering allele were pooled by meta-analysis. These findings were compared with a meta-analysis of new-onset type 2 diabetes and bodyweight change data from randomised trials of statin drugs. The effects of statins in each randomised trial were assessed using meta-analysis.

Findings: Data were available for up to 223 463 individuals from 43 genetic studies. Each additional rs17238484-G allele was associated with a mean 0·06 mmol/L (95% CI 0·05-0·07) lower LDL cholesterol and higher body weight (0·30 kg, 0·18-0·43), waist circumference (0·32 cm, 0·16-0·47), plasma insulin concentration (1·62%, 0·53-2·72), and plasma glucose concentration (0·23%, 0·02-0·44). The rs12916 SNP had similar effects on LDL cholesterol, bodyweight, and waist circumference. The rs17238484-G allele seemed to be associated with higher risk of type 2 diabetes (odds ratio [OR] per allele 1·02, 95% CI 1·00-1·05); the rs12916-T allele association was consistent (1·06, 1·03-1·09). In 129 170 individuals in randomised trials, statins lowered LDL cholesterol by 0·92 mmol/L (95% CI 0·18-1·67) at 1-year of follow-up, increased bodyweight by 0·24 kg (95% CI 0·10-0·38 in all trials; 0·33 kg, 95% CI 0·24-0·42 in placebo or standard care controlled trials and -0·15 kg, 95% CI -0·39 to 0·08 in intensive-dose vs moderate-dose trials) at a mean of 4·2 years (range 1·9-6·7) of follow-up, and increased the odds of new-onset type 2 diabetes (OR 1·12, 95% CI 1·06-1·18 in all trials; 1·11, 95% CI 1·03-1·20 in placebo or standard care controlled trials and 1·12, 95% CI 1·04-1·22 in intensive-dose vs moderate dose trials).

Interpretation: The increased risk of type 2 diabetes noted with statins is at least partially explained by HMGCR inhibition.

Funding: The funding sources are cited at the end of the paper.

PubMed Disclaimer

Figures

**Figure 1**
Association of rs17238484 genotype with type-2 diabetes-related traits Association of the rs17238484 genotype with (A) major plasma lipids fractions; (B) plasma glucose and insulin; (C) BMI and bodyweight; (D) waist and hip circumference and waist:hip ratio; and (E) risk of type 2 diabetes. Bars are 95% CIs. BMI=body-mass index.

**Figure 2**
Meta-analyses of the associations of 3-hydroxy-3-methylglutaryl-CoA reductase variants rs17238484 and rs12916 with risk of type 2 diabetes Data were analysed by fixed-effects meta-analysis.

**Figure 3**
Effect of statin treatment on new-onset type 2 diabetes Data were analysed by random-effects meta-analysis. OR=odds ratio. Case=developed type 2 diabetes. Non-case=did not develop type 2 diabetes.

**Figure 4**
Effect of statin treatment on bodyweight Data were analysed by random-effects meta-analysis. In most trials, the total number of participants without type 2 diabetes at baseline for whom bodyweight data were available was smaller than the total number for whom data were available for the analysis of new-onset type 2 diabetes.

See this image and copyright information in PMC

Comment in

Statins and type 2 diabetes: genetic studies on target.
Frayling TM. Frayling TM. Lancet. 2015 Jan 24;385(9965):310-2. doi: 10.1016/S0140-6736(14)61639-1. Epub 2014 Sep 24. Lancet. 2015. PMID: 25262342 No abstract available.
Mendelian randomisation study for statin treatment.
Morita H, Komuro I. Morita H, et al. Lancet. 2015 May 16;385(9981):1945-6. doi: 10.1016/S0140-6736(15)60957-6. Lancet. 2015. PMID: 26090639 No abstract available.
Mendelian randomisation study for statin treatment - Authors' reply.
Swerdlow DI, Preiss D, Hingorani AD, Sattar N. Swerdlow DI, et al. Lancet. 2015 May 16;385(9981):1946. doi: 10.1016/S0140-6736(15)60958-8. Lancet. 2015. PMID: 26090640 No abstract available.

Cited by

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk; Cholesterol Treatment Trialists’ (CTT) Collaboration. Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk, et al. Lancet Diabetes Endocrinol. 2024 May;12(5):306-319. doi: 10.1016/S2213-8587(24)00040-8. Epub 2024 Mar 27. Lancet Diabetes Endocrinol. 2024. PMID: 38554713 Free PMC article.
Statins as a risk factor for diabetic retinopathy: a Mendelian randomization and cross-sectional observational study.
Chen C, Zhang H, Lan Y, Yan W, Liu S, Chen Y, Xie T, Ning J, Yan X, Shang L, Han J. Chen C, et al. J Transl Med. 2024 Mar 22;22(1):298. doi: 10.1186/s12967-024-05097-8. J Transl Med. 2024. PMID: 38520016 Free PMC article.
Potential association of genetically predicted lipid and lipid-modifying drugs with rheumatoid arthritis: A Mendelian randomization study.
Huang Z, Cui T, Yao J, Wu Y, Zhu J, Yang X, Cui L, Zhou H. Huang Z, et al. PLoS One. 2024 Feb 28;19(2):e0298629. doi: 10.1371/journal.pone.0298629. eCollection 2024. PLoS One. 2024. PMID: 38416767 Free PMC article.
Antihypertensive drug targets and breast cancer risk: a two-sample Mendelian randomization study.
Zheng G, Chattopadhyay S, Sundquist J, Sundquist K, Ji J. Zheng G, et al. Eur J Epidemiol. 2024 May;39(5):535-548. doi: 10.1007/s10654-024-01103-x. Epub 2024 Feb 24. Eur J Epidemiol. 2024. PMID: 38396187 Free PMC article.
Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?
Béliard S, Mourre F, Valéro R. Béliard S, et al. Diabetologia. 2024 Jun;67(6):974-984. doi: 10.1007/s00125-024-06100-z. Epub 2024 Feb 20. Diabetologia. 2024. PMID: 38376536 Free PMC article. Review.

See all "Cited by" articles

References

1. Baigent C, Blackwell L, Emberson J. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. - PMC - PubMed
1. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121 000 patients. Am J Med. 2008;121:24–33. - PubMed
1. Cholesterol Treatment Trialists' (CTT) Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590. - PMC - PubMed
1. Kearney PM, Blackwell L, Collins R. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–125. - PubMed
1. National Center for Health Statistics . Health, United States 2010: with special feature on death and dying. National Center for Health Statistics; Hyattsville, MD: 2011. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- H1 Connect
Medical
- Genetic Alliance
- MedlinePlus Health Information

[1] Baigent C, Blackwell L, Emberson J. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. - PMC - PubMed

[2] Baigent C, Blackwell L, Emberson J. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. - PMC - PubMed

[3] O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121 000 patients. Am J Med. 2008;121:24–33. - PubMed

[4] O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121 000 patients. Am J Med. 2008;121:24–33. - PubMed

[5] Cholesterol Treatment Trialists' (CTT) Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590. - PMC - PubMed

[6] Cholesterol Treatment Trialists' (CTT) Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590. - PMC - PubMed

[7] Kearney PM, Blackwell L, Collins R. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–125. - PubMed

[8] Kearney PM, Blackwell L, Collins R. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–125. - PubMed

[9] National Center for Health Statistics . Health, United States 2010: with special feature on death and dying. National Center for Health Statistics; Hyattsville, MD: 2011. - PubMed

[10] National Center for Health Statistics . Health, United States 2010: with special feature on death and dying. National Center for Health Statistics; Hyattsville, MD: 2011. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Affiliations

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Authors

Affiliations

Abstract

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical